血浆BRAF-V600E等位基因分数作为转移性结直肠癌BRAF联合治疗预后因素
本前瞻性发现队列纳入47例BRAF-V600E突变转移性结直肠癌患者,接受BRAF抑制剂联合抗EGFR±MEK抑制剂治疗,并在独立多中心队列(n=29)中验证。血浆BRAF-V600E等位基因分数高(≥2%)与更差的无进展生存和总生存相关,探索性分析显示高分数患者从三联治疗中获益更多。
要点
- 血浆BRAF-V600E等位基因分数高(≥2%)患者无进展生存和总生存更差。
- 高BRAF等位基因分数患者从三联治疗中获益更多。
- 结果需进一步验证以优化临床分层和治疗策略。
核心结论
- ddPCR检测的血浆BRAF等位基因分数是BRAF-V600E突变转移性结直肠癌患者肿瘤负荷和侵袭性的可靠替代指标。
- 高BRAF等位基因分数患者可能从治疗强化中获益。
- 结果需进一步验证以优化临床分层和指导治疗策略。
研究设计与样本
- 前瞻性发现队列纳入47例BRAF-V600E突变患者,接受BRAF抑制剂联合抗EGFR±MEK抑制剂治疗,包括临床试验和真实世界实践。
- 结果在独立多中心队列(n=29)中验证。
- 基线血浆BRAF-V600E等位基因分数cut-off在发现队列中用微滴数字PCR(ddPCR)确定。
- 所有患者均有组织确认的BRAF-V600E突变。
主要发现
- 高等位基因分数患者肝转移频率更高且转移部位更多。
- 发现队列中位无进展生存期和总生存期分别为4.4个月和10.1个月。
- 高BRAF等位基因分数(≥2%,n=23)患者较低BRAF等位基因分数(<2%,n=24)患者无进展生存更差(HR 2.97,95%CI 1.55-5.69;P=0.001)且总生存更差(HR 3.28,95%CI 1.58-6.81;P=0.001)。
- 多变量分析中BRAF等位基因分数水平保持独立显著性。
- 验证队列中高BRAF等位基因分数与更差无进展生存相关(HR 3.83,95%CI 1.60-9.17;P=0.002),总生存有更差趋势(HR 1.86,95%CI 0.80-4.34;P=0.15)。
关键数值与推荐
- 发现队列中高BRAF等位基因分数定义为≥2%(n=23),低BRAF等位基因分数定义为<2%(n=24)。
临床怎么用
- 作者认为血浆BRAF等位基因分数可识别可能从治疗强化中获益的患者。
- 作者认为结果需进一步验证血浆BRAF等位基因分数以优化临床分层和指导治疗策略。
局限性
- 作者指出结果需进一步验证血浆BRAF等位基因分数以优化临床分层和指导治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination of a BRAF inhibitor (BRAFi) and an anti-epidermal growth factor receptor (EGFR), with or without a MEK inhibitor (MEKi), improves survival in BRAF-V600E-mutant metastatic colorectal cancer (mCRC) over standard chemotherapy. However, responses are heterogeneous and there are no available biomarkers to assess patient prognosis or guide doublet- or triplet-based regimens. In order to better characterize the clinical heterogeneity observed, we assessed the prognostic and predictive role of the plasmatic BRAF allele fraction (AF) for these combinations. PATIENTS AND METHODS: A prospective discovery cohort including 47 BRAF-V600E-mutant patients treated with BRAFi-anti-EGFR ± MEKi in clinical trials and real-world practice was evaluated. Results were validated in an independent multicenter cohort (n= 29). Plasmatic BRAF-V600E AF cut-off at baseline was defined in the discovery cohort with droplet digital PCR (ddPCR). All patients had tissue-confirmed BRAF-V600E mutations. RESULTS: Patients with high AF have major frequency of liver metastases and more metastatic sites. In the discovery cohort, median progression-free survival (PFS) and overall survival (OS) were 4.4 and 10.1 months, respectively. Patients with high BRAF AF (≥2%, n = 23) showed worse PFS [hazard ratio (HR) 2.97, 95% confidence interval (CI) 1.55-5.69; P = 0.001] and worse OS (HR 3.28, 95% CI 1.58-6.81; P = 0.001) than low-BRAF AF patients (<2%, n = 24). In the multivariable analysis, BRAF AF levels maintained independent significance. In the validation cohort, high BRAF AF was associated with worse PFS (HR 3.83, 95% CI 1.60-9.17; P = 0.002) and a trend toward worse OS was observed (HR 1.86, 95% CI 0.80-4.34; P = 0.15). An exploratory analysis of predictive value showed that high-BRAF AF patients (n = 35) benefited more from triplet therapy than low-BRAF AF patients (n = 41; PFS and OS interaction tests, P < 0.01). CONCLUSIONS: Plasmatic BRAF AF determined by ddPCR is a reliable surrogate of tumor burden and aggressiveness in BRAF-V600E-mutant mCRC treated with a BRAFi plus an anti-EGFR with or without a MEKi and identifies patients who may benefit from treatment intensification. Our results warrant further validation of plasmatic BRAF AF to refine clinical stratification and guide treatment strategies.
引用
- Ros J, Matito J, Villacampa G, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023. PMID: 36921693. doi:10.1016/j.annonc.2023.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。